Technology Innovation, People Centric
Endovastec™ is committed to provide trustworthy and universal access to state-of-the-art solutions of prolonging
and reshaping all lives, and to build a people centric enterprise ranking as a global leader of evolving and
emerging medical technologies through continuous innovation.
Products
Endovastec™ is committed to R&D, manufacturing, and sales of aortic and peripheral vascular interventional devices,
and our main products are thoracic and abdominal aortic stent grafts, stent grafts in surgical operation,
drug coated PTA balloon catheters, and PTA balloon catheters etc.
News
Endovastec™ Announces Annual Results for 2023
On 27 March, 2024, Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd. (Endovastec™,Stock code: 688016.SH) announced the annual results of Endovastec™ and its subsidiaries (the Company) for the 12 months ended 31 December, 2023 (the Reporting Period).
27 Mar 2024
Endovastec™ Completes Its First Implantation of Cratos™ in Pre-Market Clinical Study in the EU and Japan
Recently, The Cratos™ Branched Aortic Stent-Graft System (Cratos™), developed by Endovastec™, completed its first pre-market implantation at the University Hospital Zurich in Switzerland, as the starting of its CREATION clinical study. This study is instrumental for approval applications in the EU and Japan.
19 Mar 2024
Endovastec™’s Hector™ Multi-Branch Thoracic Aortic Stent-Graft Completed the First Clinical Implantation in Switzerland
Recently, Endovastec™'s Hector™ Multi-Branch Thoracic Aortic Stent-Graft System (Hector™) completed its first clinical application in Switzerland.
29 Feb 2024